Hussain Mazhar, Majeed Babar Muhammad Zafar, Hussain Muhammad Shahbaz, Akhtar Lubna
Dr. Mazhar Hussain, M.Phil-Pharmacology, Department of Pharmacology, Sheikh Zayed Medical College, Campus Police General Hospital, Jail Chowk, Rahim Yar Khan, Pakistan.
Dr. Muhammad Zafar Majeed Babar, FCPS Medicine. Department of Medicine, Medical Unit 1, Sheikh Zayed Medical College & Hospital, Rahim Yar Khan, Pakistan.
Pak J Med Sci. 2016 Nov-Dec;32(6):1396-1401. doi: 10.12669/pjms.326.11133.
To determine the effect of Vildagliptin in non-alcoholic, fatty liver disease patients with dyslipidemia.
A randomized placebo controlled trial was conducted at outpatient clinic of Medical Unit-I of Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, in which fifty eight patients of NAFLD with dyslipidemia were divided in to two, case and control groups. The case group was given tablet Vildagliptin 50mg twice a day for twelve weeks and control group was given placebo in same way. Body weight, body mass index (BMI), lipid profile, liver enzymes and ultrasound finding of fatty liver were assayed before and after treatment.
After 12 weeks treatment of vildagliptin there was significant improvement in following parameters. Body weight and BMI decreased significantly from 88 ± 11 to79 ± 12 kg (p0.036) and 30±4to 27±5 kg/m (p 0.005) respectively. Notable reduction in the value of TC, TG and LDL-C (TC:252±24 to 220±20mg/dl (p 0.031); TG: 190±24 to115±22 mg/dl (p 0.005); LDL-C 160±15 to 145±13mg/dl (p 0.004). HDL-C level increased significantly from 29±5to45±4 mg/dl (p 0.001). There was remarkable reduction in aminotransferases level (ALT: 78± 17 to 48±14IU/L (p 0.036). AST: 63.3±13 to41±11IU/L (p 0.002). There was overall 65.5% improvement in fatty liver grading on ultrasound with vildagliptin while non significant effects were seen in placebo group in all of the above parameters.
Vildagliptin exhibited beneficial effects in non-alcoholic fatty liver disease, Non-diabetic patients with dyslipidemia.
确定维格列汀对非酒精性脂肪性肝病伴血脂异常患者的疗效。
在拉希姆亚尔汗谢赫扎耶德医学院/医院第一医疗单元门诊进行了一项随机安慰剂对照试验，将58例非酒精性脂肪性肝病伴血脂异常患者分为病例组和对照组。病例组给予维格列汀片50mg，每日2次，共12周，对照组以同样方式给予安慰剂。在治疗前后测定体重、体重指数（BMI）、血脂谱、肝酶和脂肪肝的超声检查结果。
维格列汀治疗12周后，以下参数有显著改善。体重和BMI分别从88±11显著降至79±12kg（p=0.036）和30±4降至27±5kg/m²（p=0.005）。总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）值显著降低（TC：252±24降至220±20mg/dl（p=0.031）；TG：190±24降至115±22mg/dl（p=0.005）；LDL-C：160±15降至145±13mg/dl（p=0.004）。高密度脂蛋白胆固醇（HDL-C）水平从29±5显著升至45±4mg/dl（p=0.001）。转氨酶水平显著降低（谷丙转氨酶（ALT）：78±17降至48±14IU/L（p=0.036）；谷草转氨酶（AST）：63.3±13降至41±11IU/L（p=0.002）。使用维格列汀治疗后，超声检查脂肪肝分级总体改善65.5%，而安慰剂组在上述所有参数方面均无显著效果。
维格列汀对非酒精性脂肪性肝病、非糖尿病伴血脂异常患者显示出有益作用。
